{"id":"https://openalex.org/W87448443","doi":null,"title":"Lenalidomide (Revlimid\u00ae) for the first-line therapy of transplant-ineligible patients with multiple myeloma","display_name":"Lenalidomide (Revlimid\u00ae) for the first-line therapy of transplant-ineligible patients with multiple myeloma","publication_year":2012,"publication_date":"2012-09-01","ids":{"openalex":"https://openalex.org/W87448443","mag":"87448443"},"language":"en","primary_location":{"id":"mag:87448443","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/984/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007087884","display_name":"Chiara Poggiani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Poggiani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5032291905","display_name":"Anna Nachtnebel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Nachtnebel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.00914347,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":1.0},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/transplant-ineligible-patients","display_name":"transplant-ineligible patients","score":0.9779999852180481},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9919999837875366},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.765999972820282},{"id":"https://openalex.org/keywords/melphalan","display_name":"melphalan","score":0.7680000066757202},{"id":"https://openalex.org/keywords/prednisone","display_name":"prednisone","score":0.9980000257492065},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9789999723434448},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.5090000033378601},{"id":"https://openalex.org/keywords/second-primary-tumours","display_name":"second primary tumours","score":0.9319999814033508},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.7580000162124634},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.6150000095367432}],"concepts":[{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.9542054533958435},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.7428680658340454},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6847407817840576},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6661273837089539},{"id":"https://openalex.org/C2778684742","wikidata":"https://www.wikidata.org/wiki/Q2298283","display_name":"Melphalan","level":3,"score":0.643190324306488},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6058853268623352},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5763238072395325},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.5237826704978943},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.39776480197906494},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.352466881275177},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33796384930610657},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.21474221348762512},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:87448443","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/984/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2041386862","https://openalex.org/W2128084036","https://openalex.org/W3195721664","https://openalex.org/W3092332842","https://openalex.org/W6978607831","https://openalex.org/W3014523699","https://openalex.org/W3049232838","https://openalex.org/W2041048285","https://openalex.org/W2474872853","https://openalex.org/W2114217833"],"abstract_inverted_index":{"Lenalidomide":[0],"is":[1],"currently":[2],"licensed":[3],"only":[4,247],"for":[5,26,113,140,155,162,209,275,333],"previously":[6],"treated":[7],"multiple":[8],"myeloma":[9],"(MM)":[10],"patients":[11,220,251,316],"in":[12,76,91,97,103,117,127,182,189,195,217,221,226,230,237,322],"Europe.":[13],"A":[14],"phase":[15],"III":[16],"trial,":[17,32],"comprising":[18],"459":[19],"patients,":[20],"evaluated":[21],"lenalidomide":[22,33,147,158,179,224,243],"as":[23,202],"first-line":[24],"therapy":[25,35,45,63,173,259],"transplant-ineligible":[27,321],"patients.":[28],"Within":[29],"this":[30,253],"three-armed":[31],"induction":[34,172],"with":[36,55,164],"melphalan":[37,56],"and":[38,53,57,100,123,148,193,284,336],"prednisone":[39,58],"followed":[40,59],"either":[41],"by":[42,49,60],"lendalidomide":[43],"maintenance":[44,51,62,157,244,258],"(MPR-R":[46],"arm)":[47,65],"or":[48,135],"placebo":[50,54,61,165,184],"(MPR)":[52],"(MP":[64],"were":[66,138,200,207],"compared.":[67],"The":[69,235],"primary":[70,214,296],"outcome":[71],"was":[72,88,152,239],"progression-free":[73],"survival":[74],"(PFS)":[75],"the":[77,82,92,98,104,114,120,130,141,156,178,183,190,196,210,222,231,265,285,295,313],"MPR-R":[78,93,115,191],"group":[79,116,122,159,192,198],"compared":[80],"to":[81,119,129,228,242,312],"MP":[83,105,131,211,232],"group.":[84,132,212,233],"Overall,":[85],"median":[86],"PFS":[87,238],"31":[89],"months":[90,96,102,112,126],"group,":[94,106],"14":[95],"MPR":[99,121,197],"13":[101],"yielding":[107],"a":[108],"gain":[109],"of":[110,124,150,187,219,250,277,315,338],"17":[111],"comparison":[118,128],"18":[125],"Furthermore,":[133,255],"complete":[134],"partial":[136],"responses,":[137],"superior":[139],"two":[142,223],"groups":[143,180,225],"which":[144],"had":[145],"received":[146],"duration":[149],"response":[151],"significantly":[153],"longer":[154],"(MPR-R)":[160],"than":[161,181,264],"those":[163],"maintenance.":[166],"Higher":[167],"grade":[168],"haematologic":[169],"AEs":[170],"during":[171],"occurred":[174],"more":[175],"often":[176],"\nin":[177],"group;":[185],"2%":[186],"deaths":[188],"1%":[194],"respectively,":[199],"considered":[201],"treatment-related":[203],"but":[204,246],"no":[205,271,306],"results":[206],"provided":[208],"Second":[213],"tumours":[215],"developed":[216],"7%":[218],"contrast":[227],"3%":[229],"increase":[236],"mainly":[240],"attributable":[241],"therapy,":[245],"about":[248],"60%":[249],"entered":[252],"phase.":[254],"subjects":[256],"receiving":[257],"showed":[260],"better":[261],"baseline":[262],"characteristics":[263],"overall":[266],"study":[267],"population.":[268],"Also,":[269],"since":[270],"commonly":[272],"accepted":[273],"criteria":[274,298],"determination":[276],"transplant":[278],"eligibility":[279],"-besides":[280],"age-":[281],"exist":[282],"(co-morbidities":[283],"biological":[286],"age":[287],"are":[288,340],"being":[289],"considered),":[290],"it":[291],"remains":[292],"questionable":[293],"if":[294],"inclusion":[297],"(i.e.":[299],"\u226565":[300],"years,":[301],"Karnofsky":[302],"performance":[303],"score":[304],"\u226560%,":[305],"serious":[307],"medical":[308],"condition)":[309],"actually":[310],"led":[311],"enrolment":[314],"who":[317],"would":[318],"be":[319],"deemed":[320],"clinical":[323],"practice.":[324],"In":[325],"addition,":[326],"data":[327],"on":[328],"both,":[329],"adverse":[330],"events":[331],"-specifically":[332],"elderly":[334],"patients-":[335],"quality":[337],"life":[339],"missing.":[341]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}